Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA

Canan Schumann, Duc X. Nguyen, Mason Norgard, Yulia Bortnyak, Tetiana Korzun, Stephanie Chan, Anna St Lorenz, Abraham S. Moses, Hassan A. Albarqi, Leon Wong, Katherine Michaelis, Xinxia Zhu, Adam W.G. Alani, Olena R. Taratula, Stephanie Krasnow, Daniel Marks, Oleh Taratula

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass. Methods: The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous administration. The delivered mRNA directs hepatic cellular machinery to produce follistatin, a glycoprotein that increases lean mass through inhibition of negative regulators of muscle mass (myostatin and activin A). These factors are elevated in numerous disease states, thereby providing a target for therapeutic intervention. Results: Animal studies validated that mRNA-loaded nanoparticles enter systemic circulation following subcutaneous injection, accumulate and internalize in the liver, where the mRNA is translated into follistatin. Follistatin serum levels were elevated for 72 h post injection and efficiently reduced activin A and myostatin serum concentrations. After eight weeks of repeated injections, the lean mass of mice in the treatment group was ~10% higher when compared to that of the controls. Conclusion: Based on the obtained results demonstrating an increased muscle mass as well as restricted fat accumulation, this nanoplatform might be a milestone in the development of mRNA technologies and the treatment of muscle wasting disorders.

Original languageEnglish (US)
Pages (from-to)5276-5288
Number of pages13
JournalTheranostics
Volume8
Issue number19
DOIs
StatePublished - Jan 1 2018

Fingerprint

Follistatin
Nanoparticles
Muscles
Messenger RNA
Myostatin
Liver
Nanomedicine
Therapeutics
Nutritional Requirements
Injections
Muscular Atrophy
Muscular Diseases
Subcutaneous Injections
Serum
Glycoproteins
Chronic Disease
Fats
Quality of Life
Technology

Keywords

  • Activin A
  • Follistatin
  • mRNA
  • Muscle atrophy
  • Myostatin
  • Polymeric nanoparticles

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Schumann, C., Nguyen, D. X., Norgard, M., Bortnyak, Y., Korzun, T., Chan, S., ... Taratula, O. (2018). Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. Theranostics, 8(19), 5276-5288. https://doi.org/10.7150/thno.27847

Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. / Schumann, Canan; Nguyen, Duc X.; Norgard, Mason; Bortnyak, Yulia; Korzun, Tetiana; Chan, Stephanie; Lorenz, Anna St; Moses, Abraham S.; Albarqi, Hassan A.; Wong, Leon; Michaelis, Katherine; Zhu, Xinxia; Alani, Adam W.G.; Taratula, Olena R.; Krasnow, Stephanie; Marks, Daniel; Taratula, Oleh.

In: Theranostics, Vol. 8, No. 19, 01.01.2018, p. 5276-5288.

Research output: Contribution to journalArticle

Schumann, C, Nguyen, DX, Norgard, M, Bortnyak, Y, Korzun, T, Chan, S, Lorenz, AS, Moses, AS, Albarqi, HA, Wong, L, Michaelis, K, Zhu, X, Alani, AWG, Taratula, OR, Krasnow, S, Marks, D & Taratula, O 2018, 'Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA', Theranostics, vol. 8, no. 19, pp. 5276-5288. https://doi.org/10.7150/thno.27847
Schumann C, Nguyen DX, Norgard M, Bortnyak Y, Korzun T, Chan S et al. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. Theranostics. 2018 Jan 1;8(19):5276-5288. https://doi.org/10.7150/thno.27847
Schumann, Canan ; Nguyen, Duc X. ; Norgard, Mason ; Bortnyak, Yulia ; Korzun, Tetiana ; Chan, Stephanie ; Lorenz, Anna St ; Moses, Abraham S. ; Albarqi, Hassan A. ; Wong, Leon ; Michaelis, Katherine ; Zhu, Xinxia ; Alani, Adam W.G. ; Taratula, Olena R. ; Krasnow, Stephanie ; Marks, Daniel ; Taratula, Oleh. / Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. In: Theranostics. 2018 ; Vol. 8, No. 19. pp. 5276-5288.
@article{c6c928e53fe74f1ebf6e8c64d2bcd205,
title = "Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA",
abstract = "Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass. Methods: The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous administration. The delivered mRNA directs hepatic cellular machinery to produce follistatin, a glycoprotein that increases lean mass through inhibition of negative regulators of muscle mass (myostatin and activin A). These factors are elevated in numerous disease states, thereby providing a target for therapeutic intervention. Results: Animal studies validated that mRNA-loaded nanoparticles enter systemic circulation following subcutaneous injection, accumulate and internalize in the liver, where the mRNA is translated into follistatin. Follistatin serum levels were elevated for 72 h post injection and efficiently reduced activin A and myostatin serum concentrations. After eight weeks of repeated injections, the lean mass of mice in the treatment group was ~10{\%} higher when compared to that of the controls. Conclusion: Based on the obtained results demonstrating an increased muscle mass as well as restricted fat accumulation, this nanoplatform might be a milestone in the development of mRNA technologies and the treatment of muscle wasting disorders.",
keywords = "Activin A, Follistatin, mRNA, Muscle atrophy, Myostatin, Polymeric nanoparticles",
author = "Canan Schumann and Nguyen, {Duc X.} and Mason Norgard and Yulia Bortnyak and Tetiana Korzun and Stephanie Chan and Lorenz, {Anna St} and Moses, {Abraham S.} and Albarqi, {Hassan A.} and Leon Wong and Katherine Michaelis and Xinxia Zhu and Alani, {Adam W.G.} and Taratula, {Olena R.} and Stephanie Krasnow and Daniel Marks and Oleh Taratula",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/thno.27847",
language = "English (US)",
volume = "8",
pages = "5276--5288",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "19",

}

TY - JOUR

T1 - Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA

AU - Schumann, Canan

AU - Nguyen, Duc X.

AU - Norgard, Mason

AU - Bortnyak, Yulia

AU - Korzun, Tetiana

AU - Chan, Stephanie

AU - Lorenz, Anna St

AU - Moses, Abraham S.

AU - Albarqi, Hassan A.

AU - Wong, Leon

AU - Michaelis, Katherine

AU - Zhu, Xinxia

AU - Alani, Adam W.G.

AU - Taratula, Olena R.

AU - Krasnow, Stephanie

AU - Marks, Daniel

AU - Taratula, Oleh

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass. Methods: The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous administration. The delivered mRNA directs hepatic cellular machinery to produce follistatin, a glycoprotein that increases lean mass through inhibition of negative regulators of muscle mass (myostatin and activin A). These factors are elevated in numerous disease states, thereby providing a target for therapeutic intervention. Results: Animal studies validated that mRNA-loaded nanoparticles enter systemic circulation following subcutaneous injection, accumulate and internalize in the liver, where the mRNA is translated into follistatin. Follistatin serum levels were elevated for 72 h post injection and efficiently reduced activin A and myostatin serum concentrations. After eight weeks of repeated injections, the lean mass of mice in the treatment group was ~10% higher when compared to that of the controls. Conclusion: Based on the obtained results demonstrating an increased muscle mass as well as restricted fat accumulation, this nanoplatform might be a milestone in the development of mRNA technologies and the treatment of muscle wasting disorders.

AB - Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass. Methods: The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous administration. The delivered mRNA directs hepatic cellular machinery to produce follistatin, a glycoprotein that increases lean mass through inhibition of negative regulators of muscle mass (myostatin and activin A). These factors are elevated in numerous disease states, thereby providing a target for therapeutic intervention. Results: Animal studies validated that mRNA-loaded nanoparticles enter systemic circulation following subcutaneous injection, accumulate and internalize in the liver, where the mRNA is translated into follistatin. Follistatin serum levels were elevated for 72 h post injection and efficiently reduced activin A and myostatin serum concentrations. After eight weeks of repeated injections, the lean mass of mice in the treatment group was ~10% higher when compared to that of the controls. Conclusion: Based on the obtained results demonstrating an increased muscle mass as well as restricted fat accumulation, this nanoplatform might be a milestone in the development of mRNA technologies and the treatment of muscle wasting disorders.

KW - Activin A

KW - Follistatin

KW - mRNA

KW - Muscle atrophy

KW - Myostatin

KW - Polymeric nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85056786692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056786692&partnerID=8YFLogxK

U2 - 10.7150/thno.27847

DO - 10.7150/thno.27847

M3 - Article

VL - 8

SP - 5276

EP - 5288

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 19

ER -